Austria
VALANX Biotech, founded in 2017 and headquartered in Austria, is carving a niche in the Biotechnology, Health Care, and Pharmaceutical industries. The company's unique proposition lies in its GoldenSite™ technology. By offering a platform for site-specific conjugation, VALANX is reshaping how Antibody-Drug Conjugates (ADCs) are developed, ensuring reduced off-target interactions and improved efficacy.
Current focus is on developing a differentiated ADC targeting LIV-1 for combating metastatic triple-negative-breast cancer. Such innovation is aimed at fulfilling unmet needs in oncology with enhanced safety profiles and effectiveness.
The latest financial infusion, a €2.30M Seed Round on 07 November 2023, was backed by investors like SOSV, Tecnet Equity, xista science ventures, and SkyGene. The infusion is intended to accelerate the development of their pioneering ADCs, positioning VALANX as a promising player in the biotech landscape.
